Most Indian pharmaceutical companies chose a lane: make generics at scale, or invest in novel drug discovery. Glenmark Pharmaceuticals, founded in Mumbai, decided to do both — building a $1.6 billion global business while simultaneously running clinical-stage drug development programmes in respiratory, oncology, and immunology. It is a bet that has shaped the company’s identity and defined its trajectory across 80 countries.
Glenmark’s domestic business is not built on breadth — it is built on depth. In India, the company ranks second in dermatology, third in respiratory, and third in cardiac therapy. These are not accidental positions. They were cultivated over decades through dedicated field forces, physician relationships, and a product portfolio that runs from basic generics to differentiated formulations within each therapeutic area.
The dermatology franchise is the crown jewel. In a market where most generic companies treat skin conditions as a sideline, Glenmark invested in building a dermatology-first identity — from topical antifungals to advanced biologics for psoriasis. In respiratory, Ryaltris, a novel fixed-dose combination nasal spray for allergic rhinitis, received approval across EU markets and became a proof point that a generics company could bring differentiated products to regulated markets.
In oncology, Glenmark developed and commercialised biosimilars in emerging markets while investing in proprietary immuno-oncology assets. The result is a company that straddles two worlds: it generates reliable cash from branded generics in India and emerging markets while channelling that cash into an innovation pipeline that carries genuine scientific risk.
Glenmark’s geographic evolution tells the story of a company that has repeatedly rebalanced its portfolio. In FY 2019, the United States accounted for 32% of revenue and India 30%. By FY 2025, North America had grown to 34% while India had reduced to 23% — not because the domestic business shrank, but because Europe surged. European revenue grew 50% over two years through FY 2024, driven by respiratory product launches and tender wins in Germany, Spain, Poland, and the Czech Republic.
This is not the typical Indian pharma strategy of treating the US as the sole international prize. Glenmark built manufacturing capacity in five countries — India, the United States, Switzerland, the Czech Republic, and Argentina — and used that infrastructure to serve regional markets with locally relevant products. In FY 2025, Europe contributed 22% of revenue, emerging markets 21%, and North America 34%. The diversification is genuine, not cosmetic.
In FY 2025, Glenmark announced what it calls “Glenmark 3.0” — a strategic transformation from a diversified generics company to a focused, innovation-led enterprise. The pillars are respiratory, dermatology, and oncology. The logic is that Glenmark’s decades of therapeutic specialisation in these three areas give it a structural advantage that a pivot to pure innovation can exploit: existing physician relationships, regulatory expertise in complex formulations, and clinical trial capabilities that general-purpose generics companies lack.
The numbers lend some credibility to the ambition. More than 60% of FY 2025 revenue came from branded markets, where margins are higher and competition is less commodity-driven. The company holds 216 US FDA drug approvals (215 ANDAs, 1 NDA) and 131 Indian Patent Office grants. In FY 2025, Glenmark launched thirteen new products in the US alone and won eight ANDA approvals, demonstrating that the generics engine still runs while the innovation strategy takes shape.
Glenmark operates across more than 80 countries with 11 manufacturing facilities on four continents. North America is the largest market at 34% of FY 2025 revenue, followed by India at 23%, Europe at 22%, and emerging markets at 21%. In the United States, Glenmark ranks thirteenth among generic pharmaceutical companies by volume, with 216 US FDA drug approvals (215 ANDAs, 1 NDA). In India, it ranks second in dermatology and third in both respiratory and cardiac therapy.
Glenmark operates eleven manufacturing facilities across India, the United States, Switzerland, the Czech Republic, and Argentina. Four of these carry US FDA registration. The company’s API subsidiary, Glenmark Life Sciences, serves 65 countries globally, giving the parent company vertical integration from molecule synthesis through finished dosage form. In its FY 2025 US filing programme, Glenmark submitted four new ANDAs while maintaining a portfolio of 216 FDA drug approvals (215 ANDAs, 1 NDA).
Sources: Glenmark Pharmaceuticals Annual Reports FY2018–19 through FY2024–25. US FDA facility registration data. Indian patent office records.